<DOC>
	<DOCNO>NCT02054208</DOCNO>
	<brief_summary>This combined phase 1/2a clinical trial investigate safety , dose limit toxicity ( DLT ) , exploratory efficacy three repeat intraventricular administration NEUROSTEM® ( human umbilical cord blood-derived mesenchymal stem cell ) versus placebo via Ommaya reservoir 4 week interval patient Alzheimer 's disease .</brief_summary>
	<brief_title>Safety Exploratory Efficacy Study NEUROSTEM® Versus Placebo Patients With Alzheimer 's Disease</brief_title>
	<detailed_description>The study divide 2 stage : dose-escalation stage 1 randomize multiple-dose cohort parallel design stage 2.The target population enrollment study patient mild moderate Alzheimer 's disease .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>1 . Korean male female 50 85 year age 2 . Diagnosis Probable Alzheimer type mild cognitive impairment due Alzheimer 's disease ( stage A ) accord NINCDSADRDA criterion Visit 1 ( Screening ) 3 . Korea MiniMental State Examination ( KMMSE ) score 18 26 Visit 1 ( Screening ) 4 . Positive Amyloid PIBPET Florbetaben PET 5 . A subject neurodegeneration ( mild atrophy brain ) confirm MRI 6 . A subject inform clinical trial sign consent form ( unable sign , consent legally acceptable representative require ) 1 . Concurrent mental disorder ( schizophrenia , depression , bipolar disease others ) aside dementia 2 . Concurrent dementia result neurodegenerative disorder ( due infectious disease central nervous system HIV , syphilis ) , head injury , CreutzfeldJacob disease , Pick 's disease , Huntington 's disease , Parkinson 's disease 3 . Diagnosis severe white matter hyperintensitivity ( WMH ) accord CREDOS ( Clinical REsearch Center Dementia South Korea ) , define ≥ 25mm deep white matter ≥ 10mm periventricular capping/banding lengths 4 . History stroke within 3 month prior study enrollment 5 . Severe liver disorder ( equivalent double normal value ALT AST ) Visit 1 6 . Severe kidney disorder ( serum creatinine ≥1.5mg/dL ) Visit 1 7 . Pregnant lactating female 8 . Abnormal Laboratory finding Visit 1 Hemoglobin &lt; 9.5 g/dL male &lt; 9.0 g/dL female Total WBC Count &lt; 3000/mm3 Total Bilirubin &gt; = 3 mg/dL 9 . Suspected active lung disease base chest Xray Visit 1 10 . Woman childbearing age refuse practice medically acceptable contraceptive method ( post menopausal patient menstruation least 12 month consider infertile ) 11 . History screening failure clinical trial NEUROSTEM® past 6 month 12 . Participation another clinical trial past 3 month prior begin ( Week 0 ) clinical trial 13 . Bleeding disorder ( abnormal blood coagulation test result ( i.e . platelet count &lt; 150,000/mm3 , PT ≥ 1.5 INR , aPTT ≥ 1.5 x control anticoagulant antiplatelet , without anticoagulant antiplatelet therapy ) 14 . Diagnosis cancer ( body system , include brain tumor 15 . Substance/alcohol abuse 16 . Contraindicated test perform clinical trial period ( example , MRI , CT , PET ) 17 . A subject Ommaya reservoir insertion consider difficult 18 . Whom principal investigator considers inappropriate participation study due reason list</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>human umbilical cord blood derive mesenchymal stem cell</keyword>
	<keyword>stem cell</keyword>
	<keyword>alzheimer 's disease</keyword>
	<keyword>cognitive ability</keyword>
	<keyword>mesenchymal stem cell</keyword>
	<keyword>cord blood</keyword>
</DOC>